(1) Background: Neoadjuvant chemotherapy followed by interval debulking surgery is used in the treatment of advanced ovarian cancer. However, no tool can safely predict if complete cytoreduction after 3–4 cycles can be achieved. This study aims to investigate if the KELIM score can be a triage tool in the identification of patients that will be ideal candidates for interval debulking surgery (IDS). (2) Methods: We retrospectively analyzed the records of patients with high-grade serous advanced ovarian cancer that were treated in the 1st Department of Obstetrics–Gynecology, 2012–2022, with neoadjuvant chemotherapy followed by IDS. Patient characteristics, oncological outcome and follow-up information were collected. The primary outcome was the association of the KELIM score with residual disease. (3) Results: 83 patients were categorized into two groups: Group A (51 patients) with favorable (≥1) and Group B (32 patients) with unfavorable (<1) KELIM scores. A statistically significant correlation between KELIM and residual disease (p< 0.05) exists, showing that patients with a favorable KELIM score can achieve a complete IDS. Furthermore, there was a statistically significant difference in overall survival (p= 0.017), but no difference was observed in progression-free survival (p= 0.13); (4) Conclusions: KELIM seems to safely triage patients after neoadjuvant chemotherapy and decide who will benefit from IDS.
（1）背景：新辅助化疗联合间歇性肿瘤细胞减灭术是治疗晚期卵巢癌的常用方法。然而，目前尚无可靠工具能够安全预测患者在接受3-4周期化疗后能否实现完全肿瘤细胞减灭。本研究旨在探讨KELIM评分是否可作为筛选适合接受间歇性肿瘤细胞减灭术患者的有效分流工具。（2）方法：我们回顾性分析了2012-2022年间在妇产科一科接受新辅助化疗联合间歇性肿瘤细胞减灭术治疗的高级别浆液性晚期卵巢癌患者资料。收集患者临床特征、肿瘤学结局及随访信息。主要研究终点为KELIM评分与肿瘤残留状态的相关性。（3）结果：83例患者分为两组：A组（51例）KELIM评分良好（≥1），B组（32例）KELIM评分不良（<1）。KELIM评分与肿瘤残留状态存在统计学显著相关性（p<0.05），表明KELIM评分良好的患者更可能实现完全肿瘤细胞减灭。此外，两组总生存期存在显著差异（p=0.017），但无进展生存期未见统计学差异（p=0.13）。（4）结论：KELIM评分可作为新辅助化疗后安全分流患者的有效工具，有助于筛选可能从间歇性肿瘤细胞减灭术中获益的人群。
肿瘤(癌症)患者之家